Lucy is a Board Member of Silicon Valley based Life Science Angels investment group and works with many early stage startups to help them improve business strategy and investment pitch. Lucy has more than 30 years of biotech industry experiences ranging from developing therapeutics and diagnostics to research tools. She is currently the Chief Operating Officer of Auxesia Orion Inc. and focuses on orphan diseases drug development and AI-based care management. From 2008 to 2014, she served as Senior Vice President of Corporate and Business Development at Crescendo Bioscience Inc. During her six years at Crescendo, she helped raised $90M in venture funding, supported the development and commercialization of a novel rheumatoid arthritis test and the company was acquired by Myriad Genetics in early 2014.
Prior to joining Crescendo, she was Vice President, Technology Management and Head of the U.S. Chief Technology Office for Roche Diagnostics for five years, where she built a global team focusing on life sciences, diabetes care, centralized and molecular diagnostics technology scouting and assessment to support corporate strategic planning and M&A. Lucy had also held various Life Sciences marketing and product development positions at Roche Applied Sciences and PE Applied Biosystems (now Thermo Fisher Scientific). In her early career, she devoted 10 years in drug R&D at Genentech (now Roche) and Bristol-Myers Squibb.
Lucy holds a BS degree in Botany from National Taiwan University in Taiwan, an MS degree in Plant Biology from University of Illinois at Urbana-Champaign and an MBA from St. Mary’s College at Moraga, California.